Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 07, 2018 5:20pm EDT
Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer Jun 07, 2018 8:00am EDT
Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association May 17, 2018 9:00am EDT
Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress May 08, 2018 7:05am EDT
Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies in Oncology, Autoimmune and Other Diseases May 08, 2018 7:00am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 07, 2018 5:30pm EDT
Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development May 07, 2018 8:00am EDT
Atara Biotherapeutics Expands Commercial Leadership Team with the Appointment of Manuela Maronati as General Manager, Europe May 01, 2018 8:00am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 09, 2018 4:45pm EDT
